The identification of effective interventions against the coronavirus disease 2019 (COVID-19) pandemic has become a health priority . The rational treatment of a disease is based on the knowledge of its pathophysiology, the identification of a therapeutic target and the confirmation of the efficacy and safety of the selected therapeutic intervention in randomised controlled trials . However, we are facing the COVID-19 pandemic without a clear understanding of the pathophysiology of the disease . As we are fighting against a viral infection, drugs previously developed or approved to treat other viral infections or that exhibit a broad-spectrum antiviral activity, anti-inflammatory drugs and drugs against cytokine storm are currently being tested . Unfortunately, the efficacy and safety of these medications remain uncertain, and some may increase the risk of cardiovascular complications in patients with COVID-19. Thus, at the present time, due to the lack of solid scientific data to support a therapeutic strategy, we truly are shooting in the dark with the treatment of COVID-19 . We must wait for the results of ongoing randomised, controlled studies before the widespread adoption of these drugs . In the meantime, investigational anti-COVID-19 drugs should be used in hospitals or as part of clinical trials.